ClinicalTrials.gg
CompletedNCT06277167Updated May 1, 2024

A Phase I Study in Healthy Participants

A Phase 1 interventional study of Human interferon alfa 1b inhalation solution and Human interferon alfa 1b inhalation solution placebo in Healthy Participants, sponsored by Kexing Biopharm Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-01.

Sponsored by Kexing Biopharm Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2023, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A Randomized, Double-Blind, Placebo-Controlled Phase-I Clinical Study to Evaluate the Tolerability, Safety and PK Profiles of Human interferon alfa 1b inhalation solution in Healthy Adult Subjects after Administration of Single Ascending Doses and Multiple Ascending Doses

Read the detailed description

Primary objective:To evaluate the tolerability and safety of single and multiple aerosol inhalation of Human interferon alfa 1b inhalation solution in healthy adult subjects.

Secondary objectives: To evaluate the pharmacokinetic (PK) profiles of single and multiple aerosol inhalation of Human interferon alfa 1b inhalation solution in healthy adult subjects and to evaluate the immunogenicity of single and multiple aerosol inhalation of Human interferon alfa 1b inhalation solution in healthy adult subjects

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Kexing Biopharm Co., Ltd. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult males or females aged 18-45 years;
  2. Male body weight ≥45 kg, male body weight ≥50 kg, and (BMI): 19.0-26.0 kg/m2 (both inclusive), BMI =body weight (kg)/height 2 (m2);
  3. The subjects voluntarily participate in the study and sign an form before the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who participated in any clinical studies of drugs or took study drugs within 3 months prior to the administration of study drug;
  2. Subjects who have undergone surgery within 3 months prior to screening or who plan to undergo surgery during the study or who have undergone surgery that would affect the absorption, distribution, metabolism, and excretion of drugs; subjects with a previous history of diseases of cardiovascular system, blood and lymphatic system, respiratory system, urinary system, endocrine, immune, mental and nervous system (such as epilepsy) that are ;
  3. Subjects with a history of respiratory system diseases, such as acute exacerbation of , pulmonary fibrosis, pulmonary hypertension, pulmonary edema, pulmonary interstitial disease, bronchial asthma, paradoxical bronchospasm, or throat ulcer and edema, or subjects with previous surgery of throat, trachea/bronchi and lung, or subjects with upper and lower respiratory tract infection and acute sinusitis caused by virus or bacteria within the 4 weeks prior to the use of study drug that are clinically significant or render them unsuitable to participate in the study in the opinion of the investigator;
  4. Subjects with ocular diseases or thyroid-related diseases that are clinically significant or render them unsuitable to participate in the study in the opinion of the investigator;
  5. Subjects with a history of drug allergy (antibiotics, interferon products, etc.), or a specific history of allergy (asthma, urticaria, eczema, etc.), or allergic constitution (such as allergy to two or more drugs, food, pollen, etc.);
  6. Subjects who cannot tolerate aerosol inhalation;
  7. Subjects who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or vitamins within14 days prior to screening;
  8. Subjects who have received vaccine within 4 weeks prior to the first dose, or subjects who plan to receive vaccine within 4 weeks after the last dose;
  9. Subjects who have had non-physiological blood loss of ≥300 mL within 3 months before the first dose (including trauma, blood collection, blood donation); or subjects who plan to donate blood during the study or within 30 days after the last dose;
  10. Subjects who have had a history of drug use or abuse within 6 months prior to screening;
  11. Subjects who have smoked within 3 months prior to screening, or who cannot stop using any tobacco products during the study;
  12. Subjects who have consumed more than 14 glasses of alcohol per week (1 glass =150 mL wine, or 360 mL beer, or 45 mL spirits) within 3 months prior to screening;
  13. Subjects who cannot tolerate venipuncture for blood collection or have potential blood collection difficulties, or subjects who feel dizzy and sick at the sight of blood or needle;
  14. Subjects who have special requirements for diet and cannot follow a standardized diet;
  15. Subjects who have a birth plan, or are unable to voluntarily take effective measures, or have a sperm/egg donation plan during the study period and within 3 months after the last dose; female subjects who are pregnant or lactating;
  16. Subjects with clinically significant abnormalities on physical examinations, , vital signs, chest X-rays, lung function, and laboratory tests (as judged by the clinician);
  17. Pulmonary function test: subjects with measured/predicted ≤80% or FVC≤ 80% of expected value;
  18. Subjects who have positive urine nicotine test results;
  19. Subjects who have positive urine drug test results;
  20. Subjects who have positive alcohol breath results;
  21. Subjects who cannot use aerosol device correctly or who do not pass the aerosol dosing training;
  22. Subjects who cannot complete this study due to other reasons, or subjects who are unsuitable to participate in this clinical study due to other various reasons;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Human interferon alfa 1b inhalation solution (SAD)

    Human interferon alfa 1b inhalation solution:200,000 IU, 600,000 IU, 1,200,000 IU, and 1,80,000 IU dose groups

    Drug: Human interferon alfa 1b inhalation solution

  • Placebo comparator
    Human interferon alfa 1b inhalation solution placebo (SAD)

    Human interferon alfa 1b inhalation solution placebo :200,000 IU, 600,000 IU, 1,200,000 IU, and 1,80,000 IU dose groups

    Drug: Human interferon alfa 1b inhalation solution placebo

  • Experimental
    Human interferon alfa 1b inhalation solution (MAD)

    Human interferon alfa 1b inhalation solution drug product:1,200,000 IU, and 1,80,000 IU dose groups

    Drug: Human interferon alfa 1b inhalation solution

  • Placebo comparator
    Human interferon alfa 1b inhalation solution placebo (MAD)

    Human interferon alfa 1b inhalation solution placebo :1,200,000 IU, and 1,80,000 IU dose groups

    Drug: Human interferon alfa 1b inhalation solution placebo

Interventions

  • DrugHuman interferon alfa 1b inhalation solution

    Participants will receive Human interferon alfa 1b inhalation solution orally for a single dose.

  • DrugHuman interferon alfa 1b inhalation solution placebo

    Participants will receive Human interferon alfa 1b inhalation solution placebo orally for a single dose.

  • DrugHuman interferon alfa 1b inhalation solution

    Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).

  • DrugHuman interferon alfa 1b inhalation solution placebo

    Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution placebo administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).

06

What researchers measure

Primary outcomes

  1. TEAEs

    The adverse events and incidence of treatment-emergent adverse events(TEAEs)

    Time frame: Day 1 up to 29 or Day 1 up to 32

  2. (ADRs)

    The adverse events and incidence of adverse drug reactions (ADRs)

    Time frame: Day 1 up to 29 or Day 1 up to 32

  3. (SAE)

    The adverse events and incidence of serious adverse events (SAE)

    Time frame: Day 1 up to 29 or Day 1 up to 32

  4. TEAEs that lead to subject discontinuation from the study

    The adverse events and incidence of TEAEs that lead to subject discontinuation from the study

    Time frame: Day 1 up to 29 or Day 1 up to 32

Secondary outcomes

  1. Cmax After a Single Dose of GB05 Drug Product

    The maximum concentration (Cmax) of GB05 Drug Product

    Time frame: Day 1 up to 3

  2. Tmax After a Single Dose of GB05 Drug Product

    The maximum concentration (Tmax) of GB05 Drug Product

    Time frame: Day 1 up to 3

  3. AUC0-t and AUC0-inf After a Single Dose of GB05 Drug Product

    The area under the concentration-time curve (AUC0-t and AUC0-inf) of GB05 Drug Product.

    Time frame: Day 1 up to 3

  4. t1/2 After a Single Dose of GB05 Drug Product

    The elimination half-life (t1/2) of GB05 Drug Product

    Time frame: Day 1 up to 3

  5. Ke After a Single Dose of GB05 Drug Product

    The elimination rate constant (Ke) of GB05 Drug Product

    Time frame: Day 1 up to 3

  6. Vd After a Single Dose of GB05 Drug Product

    The apparent distribution volume (Vd) of GB05 Drug Product.

    Time frame: Day 1 up to 3

  7. MRT After a Single Dose of GB05 Drug Product

    The average residence time (MRT) of GB05 Drug Product

    Time frame: Day 1 up to 3

  8. CL After a Single Dose of GB05 Drug Product

    The clearance rate (CL) of GB05 Drug Product

    Time frame: Day 1 up to 3

  9. Cmax,ss After Multiple Doses of GB05 Drug Product

    The maximum concentration at steady state (Cmax,ss) of GB05 Drug Product

    Time frame: Day 1 up to 10

  10. Cmin,ss After Multiple Doses of GB05 Drug Product

    The minimum concentration at steady state (Cmin,ss) of GB05 Drug Product

    Time frame: Day 1 up to 10

  11. Css_av After Multiple Doses of GB05 Drug Product

    The average steady-state plasma concentration (Css_av) of GB05 Drug Product

    Time frame: Day 1 up to 10

  12. DF After Multiple Doses of GB05 Drug Product

    The degree of fluctuation in the concentration during the dosing interval (DF) of GB05 Drug Product

    Time frame: Day 1 up to 10

  13. (Cmax,ss-Cmin,ss)/Cmin,ss After Multiple Doses of GB05 Drug Product

    The fluctuation amplitude \[(Cmax,ss-Cmin,ss)/Cmin,ss\] of GB05 Drug Product

    Time frame: Day 1 up to 10

  14. ADA

    The Number and Percentage of Participants of anti-drug antibody (ADA)

    Time frame: Day 1 up to 29 or Day 1 up to 32

  15. NAb

    The Number and Percentage of Participants of neutralizing antibody (NAb).

    Time frame: Day 1 up to 29 or Day 1 up to 32

07

Study locations

1 site
  • The Third Hospital of Changsha
    Changsha, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Apr 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Feb 26, 2024
StartActual
Jan 7, 2023
Primary completionActual
Apr 21, 2023
CompletionActual
Apr 21, 2023
Last update
May 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06277167
Lead sponsor
Kexing Biopharm Co., Ltd.
Collaborators
Guoxin Pharmaceutical Technology (Beijing) Co., Ltd., The Third Hospital of Changsha, Beijing SSYP Data Technology Development Co.,Ltd., United-Power Pharma Tech(Shanghai)Co., Ltd.
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Jan 7, 2023
Primary completion
Apr 21, 2023
Completion
Apr 21, 2023
Last update
May 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion